Investment Scenario Analysis: Eli Lilly (LLY) and Summit Therapeutics (SMMT) Benchmarked Against the S&P 500 Index

Prepared by Richstorm.co  

Purpose of This Report

This report summarizes a scenario analysis comparing two pharmaceutical investment opportunities — Eli Lilly (LLY) and Summit Therapeutics (SMMT) — against the S&P 500 index as a benchmark across one-year, two-year, and five-year time horizons.

The analysis is illustrative and educational in nature. It is designed to demonstrate the range of possible outcomes across different investment types — a large-cap pharma platform company, a small-cap single-asset biotech, and a broad market index — and to show how the risk-return profile differs fundamentally across each category.

Important:  All return figures in this report are scenario ranges, not predictions or guarantees. Actual returns may differ materially from any scenario presented. This report is for informational purposes only and does not constitute investment advice.

Investment Profile Comparison

The table below summarizes the key characteristics of each investment as of May 2026.

The three investments represent fundamentally different risk-return profiles. The S&P 500 is the passive baseline — broad diversification, historical reliability, no individual company risk. LLY is a platform bet on the continued expansion of the GLP-1 franchise and pipeline optionality. SMMT is a binary event bet on a single drug's regulatory and commercial outcome.

The S&P 500 Baseline

The S&P 500 is the most appropriate benchmark for evaluating individual stock investment decisions because it represents the return available to any investor without taking on individual company risk. The historical average annual return of the S&P 500 is approximately 10.4% over the last 100 years with dividends reinvested, and 11.7% over the last 50 years.

Historical Context

The five-year average from 2021 through 2025 was approximately 14.4%, somewhat above the long-run average, reflecting the extraordinary technology-driven bull market of that period. For 2026 specifically, Wall Street consensus projects approximately 12% annual return, with all major strategists forecasting positive performance.

Baseline Return Expectations

Based on historical averages and current consensus, the S&P 500 baseline scenarios are as follows. Over one year, the base case is 10 to 12% with dividends reinvested, and a realistic bear case of -15% to 0% in a significant economic downturn. Over two years cumulatively, the base case is approximately 21 to 25%. Over five years cumulatively, the base case is 61 to 80% assuming 10 to 12% annual compounding.

Key insight: The S&P 500 has no five-year rolling period in modern history where it has produced a loss when dividends are reinvested. It is the most reliable long-term compounder available to retail investors — and the standard against which all individual stock bets should be measured.

Eli Lilly (LLY) — Platform Cycle Bet

Investment Thesis

Eli Lilly represents the clearest current pharmaceutical platform cycle investment opportunity. The company has built the most strategically differentiated pipeline in the mega-cap pharmaceutical peer group, anchored by the tirzepatide GLP-1 franchise and the imminent oral GLP-1 product orforglipron.

Key Clinical and Commercial Facts

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) has captured approximately 60% of the U.S. GLP-1 market as of early 2026. Orforglipron, an oral GLP-1 receptor agonist, completed Phase 3 trials meeting all primary and secondary endpoints — the first oral GLP-1 to do so with results comparable to injectable class members. FDA submission is anticipated in 2026 with approval potentially in 2027.

At current prices of approximately $935, LLY trades at roughly 38x forward earnings — a significant premium to the S&P 500 average of 21x. Analyst consensus price targets average approximately $1,238, implying approximately 32% upside on the base case. However, one independent fair value model places intrinsic value at $546, suggesting the market has already priced significant future success into current valuations.

LLY Scenario Analysis

1-Year Scenarios

Bull case — FDA accepts orforglipron filing, strong commercial execution, no major pricing shock: stock moves toward $1,200 to $1,400. Return: +25% to +50%. Base case — steady execution, IRA negotiations proceed without catastrophic impact: stock tracks earnings growth. Return: +10% to +25%. Bear case — significant IRA pricing outcome or orforglipron safety signal emerges: multiple contracts, stock declines. Return: -20% to -40%.

2-Year Scenarios

Bull case — orforglipron approved and showing strong early commercial uptake, expanding the addressable patient population materially: Return: +50% to +90%. Base case — moderate oral GLP-1 uptake, steady franchise growth: Return: +20% to +50%. Bear case — pricing pressure materializes, oral GLP-1 adoption slower than expected: Return: -10% to -30%.

5-Year Scenarios

Bull case — orforglipron becomes a $15B+ product, donanemab achieves broad Alzheimer's prevention adoption, retatruitide approved, pipeline delivers across oncology and gene editing: Return: +100% to +200%. Base case — GLP-1 franchise matures, IRA takes a meaningful bite, pipeline partially delivers, 10 to 15% annual earnings growth: Return: +60% to +100%. Bear case — generic or biosimilar GLP-1 entry earlier than expected, pipeline disappoints, multiple compression: Return: flat to -20%.

LLY vs. S&P 500 Assessment

In the base case across all time horizons, LLY and the S&P 500 are not dramatically different. LLY only clearly outperforms in the bull case. The bear case significantly underperforms the index. At 38x forward earnings, investors are already paying for the bull case to occur. The risk-adjusted case for LLY over the S&P 500 is real but more modest from current valuations than the strong 2019 to 2024 performance period suggested.

Summit Therapeutics (SMMT) — Binary Event Bet

Investment Thesis

Summit Therapeutics represents a classic small-cap biotech binary event investment. The company's entire value rests on a single asset — ivonescimab — a bispecific antibody combining PD-1 checkpoint inhibition with anti-VEGF activity. The drug has demonstrated Phase 3 superiority over pembrolizumab (Keytruda) in certain non-small cell lung cancer settings — a genuinely remarkable clinical result given Keytruda's status as the world's best-selling drug.

Key Clinical and Regulatory Facts

Ivonescimab has four positive Phase 3 readouts and two existing approvals in China through a partnership with Akeso Biotech. The FDA accepted Summit's BLA (Biologics License Application) for ivonescimab in EGFR-mutated non-small cell lung cancer with a PDUFA goal date of November 14, 2026. Overall survival data from the HARMONi-6 trial will be featured at the ASCO 2026 Annual Meeting Plenary Session — a major visibility event. Phase 3 data shows hazard ratios of 0.51 to 0.60, meaning ivonescimab reduced the risk of disease progression by 40 to 49% compared to pembrolizumab.

The company is currently pre-revenue, burning approximately $0.24 per share per quarter, with 15 Phase 3 studies all involving one drug. One independent DCF model estimates fair value at $95.66 against a current stock price of approximately $16 to $21 — implying very large potential upside if the drug delivers commercially.

SMMT Scenario Analysis

1-Year Scenarios

The defining event within the next 12 months is the FDA PDUFA date of November 14, 2026. Bull case — FDA approves ivonescimab, ASCO data confirms strong overall survival benefit: stock potentially moves to $40 to $60 from current ~$20. Return: +100% to +200%. Base case — FDA approves with label restrictions, mixed ASCO data: Return: +20% to +60%. Bear case — FDA rejects or issues Complete Response Letter: Return: -50% to -70%. Tail risk — safety signal emerges pre-approval: Return: -70% to -90%.

2-Year Scenarios

By year two the FDA decision will be known and early commercial trajectory visible. Bull case — approved, strong early traction, HARMONi-3 positive, acquisition interest from large pharma: Return: +200% to +400%. Base case — approved, modest commercial uptake, revenue ramping: Return: +50% to +150%. Bear case — rejected or poor commercial uptake: Return: -50% to -75%.

5-Year Scenarios

Bull case — approved across multiple NSCLC indications, expansion to colorectal and other tumor types, potential large pharma acquisition at significant premium: Return: +500% to +1000%. Base case — approved in one or two indications, moderate commercial penetration, revenue of $500M to $1B by year 5: Return: +100% to +250%. Bear case — approval but commercial failure, cash burn continues, dilutive financing: Return: -25% to -60%. Catastrophic case — multiple regulatory failures: Return: -90% or more.

SMMT vs. S&P 500 Assessment

SMMT's bull case return at every time horizon dwarfs both LLY and the S&P 500. The 5-year bull case of 500% to 1000% is genuinely achievable if the drug is approved and gains commercial traction. However the S&P 500 has essentially no 5-year scenario where an investor loses significant money. SMMT has a very real scenario at every horizon where most or all of the investment is lost. This asymmetry — extraordinary upside, severe downside — defines small-cap biotech investing and is why position sizing is critical: most sophisticated investors would size SMMT at 1 to 3% of a portfolio maximum.

Combined Scenario Summary

The table below consolidates all three investments across all scenarios and time horizons for direct comparison. Green figures indicate positive returns, red figures indicate negative returns.

Risk and Upside Summary

Key Analytical Conclusions

1. The S&P 500 base case is the hardest benchmark to consistently beat

Ten to twelve percent annual returns with near-zero catastrophic risk over five-year horizons is a genuinely high bar. Both LLY and SMMT require specific clinical, regulatory, and commercial outcomes to materially outperform it on a risk-adjusted basis.

2. LLY's best return window may have already passed

The 500% return from 2019 to 2024 was driven by investors recognizing the GLP-1 platform before the market. That recognition is now consensus. At 38x forward earnings, the base case return from LLY is broadly comparable to — not dramatically superior to — the S&P 500. The bull case is real but requires execution the market has not yet fully priced.

3. SMMT is not an investment — it is a structured bet

The November 14, 2026 FDA PDUFA date is the single most important near-term event for SMMT investors. The drug's Phase 3 superiority over Keytruda is a genuinely remarkable clinical result. But clinical superiority does not guarantee commercial success against a drug with 15 years of physician familiarity and Merck's commercial infrastructure. The binary nature of the outcome demands strict position sizing discipline.

4. Return potential and due diligence requirement are directly correlated

The S&P 500 requires almost no due diligence. LLY requires understanding of pipeline execution, payer dynamics, and valuation context. SMMT requires deep clinical knowledge, regulatory pathway assessment, and competitive landscape analysis. The extra return potential of each comes with proportionally more analytical work — and proportionally more risk of being wrong.

5. Time horizon is the most important variable

Over one year, all three investments carry meaningful uncertainty driven by macro, sentiment, and specific catalysts. Over five years, the S&P 500's reliability increases dramatically, LLY's platform has more time to deliver, and SMMT either succeeds commercially or does not. Longer time horizons reduce noise and increase the signal of fundamental business quality — which is why they consistently reward patient investors.

Final framing:  The S&P 500 is the right choice for investors who want certainty of process and do not want to do the work. LLY is the right choice for investors who believe the GLP-1 platform has more room to run and are comfortable with elevated valuation risk. SMMT is the right choice for investors with genuine clinical analytical capability, high risk tolerance, and strict position sizing discipline. All three can coexist in a well-constructed portfolio — in very different proportions.

If you found this analysis useful, RichStorm publishes independent pharma investment research grounded in science. Subscribe free to receive new insights directly in your inbox. [Subscribe here]

Prepared by RichStorm LLC | May 2026 | For informational purposes only. Not investment advice. All return scenarios are illustrative ranges based on analytical judgment, not predictions or guarantees of future performance. S&P 500 historical return data sourced from public market data. LLY and SMMT data sourced from SEC filings, company investor relations materials, and publicly available analyst estimates. Past performance is not indicative of future results. RichStorm LLC is not a registered investment adviser. Readers should consult a qualified financial adviser before making any investment decisions.